• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis. Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): a case-controlstudy of hospitalized patients

Giuseppe

Emeritus
[Source: Clinical Infectious Diseases, full page: (LINK). Abstract, edited.]


Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): a case-controlstudy of hospitalized patients

Jaffar A. Al-Tawfiq 1,2,*, Kareem Hinedi 1, Jihad Ghandour 1, Hanan Khairalla 1, Samir Musleh 1, Alaa Ujayli 1, and Ziad A Memish 3

Author Affiliations: <SUP>1</SUP>Specialty Internal Medicine, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia <SUP>2</SUP>Indiana University School of Medicine, Indiana, USA <SUP>3</SUP>Deputy Minister for Public Health, and Director WHO Collaborating Center for Mass Gathering Medicine Ministry of Health, and Professor, Al-Faisal University, Riyadh, Saudi Arabia

*Corresponding author: Dr. Jaffar A. Al-Tawfiq, P.O. Box 76; Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia. E-mail address: jaffar.tawfiq@aramco.com; jaltawfi@yahoo.com, Tel: +966-13-877-3524; Fax: +966-13-877-3790
Alternate corresponding author: Dr Kareem Hinedi (kareem.hinedi@aramco.com)

<CITE><ABBR>Clin Infect Dis.</ABBR> (2014) doi: 10.1093/cid/ciu226 </CITE>First published online: April 9, 2014


Abstract

Background.

There is a paucity of data regarding the differentiating characteristics of laboratory confirmed cases and negative Middle East Respiratory Syndrome coronavirus (MERS-CoV) patients.


Methods.

This is a hospital-based case-control study comparing MERS-CoV positive patients (cases) with MERS-CoVnegative controls.


Results.

A total of 17 cases and 82 controls with a mean age of 60.7 years and 57 years, respectively (P=0.5532) were included. No statistical differences were observed in relation to gender, the presence of a fever or cough, and the presence of a single or multi-lobar infiltrate on chest x-ray. The cases were more likely to be overweight than the control group (mean BMI 32 vs. 27.8; P=0.0353), to have diabetes mellitus (87% vs. 47%; OR=7.24; P=0.015),and end-stage renal disease (33% vs. 7%; OR=7; P=0.012). At the time of admission, tachypnea (27% vs. 60%; OR=0.24; P=0.031) and respiratory distress (15% vs. 51%; OR=0.15; P=0.012) were less frequentamong cases. MERS-CoV patients were more likely to have a normal WBC than the control group (82% vs. 52%; OR=4.33; P=0.029). Admission chest x-rays with interstitial infiltrates were more frequent in cases than in controls (67% vs. 20%; OR=8.13; P=0.001). Cases were more likely to be admitted to the ICU (53% vs. 20%; OR=4.65; P=0.025) and to have a high mortality rate among (76% vs. 15%; OR=18.96; P<0.001).


Conclusions.

MERS-CoV patients were more likely to be overweight, have a normal WBC on admission, and interstitial infiltrates on initial chest x-ray, and had a higher mortality rate.


Received January 13, 2014. Accepted March 25, 2014.

? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.


-
------
 
Back
Top